Effect of MDR1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype

被引：0
|
作者：
Vanhove, Thomas [1 ]
Annaert, Pieter [2 ]
Kuypers, Dirk R. J. [1 ]
机构：
[1] Univ Hosp Leuven, Nephrol & Renal Transplantat, Leuven, Belgium
[2] Univ Leuven, KU Leuven, Pharmaceut & Pharmacol Sci, Leuven, Belgium
来源：
TRANSPLANTATION | 2016年 / 100卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
420.13
引用
收藏
页码：S167 / S168
页数：2
相关论文
共 50 条
  • [41] Evaluating the Effect of CYP3A4 and CYP3A5 Polymorphisms on Cyclosporine, Everolimus and Tacrolimus Pharmacokinetics in Renal Transplantation Patients
    Moes, D. J. A. R.
    Swen, J. J.
    den Hartigh, J.
    van der Straaten, T.
    van der Heide, Homan J. J.
    Bemelman, F.
    de Fijter, J. W.
    Guchelaar, H. J.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 672 - 672
  • [42] Donors'CYP3A5 and Recipients'CYP3A4 and TBL Predict Tacrolimus Disposition and New-Onset Hypertension in Liver Transplant Patients
    Liu, Y.
    Zhang, T.
    Zhang, X.
    Fan, J.
    TRANSPLANTATION, 2017, 101 (05) : 377 - 377
  • [43] Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant
    Hannachi, Ibtissem
    Ben Fredj, Nadia
    Chadli, Zohra
    Ben Fadhel, Najah
    Ben Romdhane, Haifa
    Touitou, Yvan
    Boughattas, Naceur A.
    Chaabane, Amel
    Aouam, Karim
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2020, 396
  • [44] In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients
    de Jonge, H.
    de Loor, H.
    Verbeke, K.
    Vanrenterghem, Y.
    Kuypers, D. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (03) : 366 - 375
  • [45] Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis
    Zuo, Xiao-cong
    Ng, Chee M.
    Barrett, Jeffrey S.
    Luo, Ai-jing
    Zhang, Bi-kui
    Deng, Chen-hui
    Xi, Lan-yan
    Cheng, Ke
    Ming, Ying-zi
    Yang, Guo-ping
    Pei, Qi
    Zhu, Li-jun
    Yuan, Hong
    Liao, Hai-qiang
    Ding, Jun-jie
    Wu, Di
    Zhou, Ya-nan
    Jing, Ning-ning
    Huang, Zhi-jun
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (05): : 251 - 261
  • [46] INFLUENCE OF CYP3A4, CYP3A5, POR AND ABCB1 GENES ON TACROLIMUS RESPONSE IN LIVER TRANSPLANT RECIPIENTS
    Naldi, Graziella D'A. R.
    Pereira, Thales Dalessandro
    Fossaluza, Victor
    Nacif, Lucas
    Carneiro D'Albuquerque, Luiz Augusto
    Carrilho, Flair J.
    Ono, Suzane Kioko
    HEPATOLOGY, 2022, 76 : S1281 - S1282
  • [47] Influence of CYP3A4*1B and CYP3A5*1 polymorphisms on tacrolimus exposure in Tunisian kidney transplant recipients
    Ben Fredj, N.
    Kerkni, E.
    Baptiste, W. Jean
    Chaabane, A.
    Hammouda, M.
    Kolsi, A.
    Skhiri, H.
    Boughattas, N.
    Aouam, K.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 62 - 62
  • [48] Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients
    Kuypers, Dirk R.
    de Jonge, Hylke
    Naesens, Maarten
    Vanrenterghem, Yves
    PHARMACOGENETICS AND GENOMICS, 2008, 18 (10): : 861 - 868
  • [49] Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients
    Chowbay, B
    Cumaraswamy, S
    Cheung, YB
    Zhou, QY
    Lee, EJD
    PHARMACOGENETICS, 2003, 13 (02): : 89 - 95
  • [50] Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation
    Zhang, X
    Liu, ZH
    Zheng, JM
    Chen, ZH
    Tang, Z
    Chen, JS
    Li, LS
    CLINICAL TRANSPLANTATION, 2005, 19 (05) : 638 - 643
12345